Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dyne Therapeutics, Inc.

7.85
+0.38005.09%
Post-market: 7.79-0.0600-0.76%16:29 EDT
Volume:1.45M
Turnover:11.34M
Market Cap:888.00M
PE:-2.33
High:8.01
Open:7.42
Low:7.42
Close:7.47
Loading ...

Dyne Therapeutics Inc - Expects Completion of Enrollment for Registrational Expansion Cohort in Mid-2025

THOMSON REUTERS
·
10 Jan

Jefferies healthcare analyst holds an analyst/industry conference call

TIPRANKS
·
19 Dec 2024

Baird Initiates Dyne Therapeutics at Outperform With $46 Price Target

MT Newswires Live
·
13 Dec 2024

Dyne Therapeutics Initiated at Outperform by Baird

Dow Jones
·
13 Dec 2024

Dyne Therapeutics Inc : Baird Initiates Coverage With Outperform Rating; Target Price $46

THOMSON REUTERS
·
13 Dec 2024

Dyne, Avidity initiated at outperform by RBC on DM1 drugs

seekingalpha
·
27 Nov 2024

RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target

MT Newswires Live
·
26 Nov 2024

U.S. RESEARCH ROUNDUP-Allstate, Mongodb, Primerica

Reuters
·
26 Nov 2024

Dyne Therapeutics initiated with an Outperform at RBC Capital

TIPRANKS
·
26 Nov 2024

Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

Insider Monkey
·
22 Nov 2024

U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart

Reuters
·
20 Nov 2024

Dyne Therapeutics Reveals Q3 Results and Trial Updates

TIPRANKS
·
14 Nov 2024

Dyne Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
14 Nov 2024

Dyne Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Dyne Therapeutics' Q3 Loss Narrows

MT Newswires Live
·
12 Nov 2024

Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026

Benzinga
·
12 Nov 2024

Dyne Therapeutics reports Q3 EPS (96c), consensus (71c)

TIPRANKS
·
12 Nov 2024

Dyne Therapeutics Shares Down 2.2% After JP Morgan Cuts to Neutral From Overweight

THOMSON REUTERS
·
24 Oct 2024

BUZZ-Dyne Therapeutics falls as J.P. Morgan downgrades to 'neutral'

Reuters
·
24 Oct 2024

Dyne Therapeutics Shares Down 2.6% Premarket After JP Morgan Cuts to Neutral From Overweight

THOMSON REUTERS
·
24 Oct 2024